JP5951490B2 - 非複合ボツリヌス神経毒素を精製するための方法およびシステム - Google Patents

非複合ボツリヌス神経毒素を精製するための方法およびシステム Download PDF

Info

Publication number
JP5951490B2
JP5951490B2 JP2012535338A JP2012535338A JP5951490B2 JP 5951490 B2 JP5951490 B2 JP 5951490B2 JP 2012535338 A JP2012535338 A JP 2012535338A JP 2012535338 A JP2012535338 A JP 2012535338A JP 5951490 B2 JP5951490 B2 JP 5951490B2
Authority
JP
Japan
Prior art keywords
botulinum toxin
exchange column
column
unconjugated
hydrophobic interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012535338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508388A5 (enExample
JP2013508388A (ja
Inventor
カーチス エル． リュエッグ
カーチス エル． リュエッグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revance Therapeuticals Inc
Original Assignee
Revance Therapeuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43879799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5951490(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeuticals Inc filed Critical Revance Therapeuticals Inc
Publication of JP2013508388A publication Critical patent/JP2013508388A/ja
Publication of JP2013508388A5 publication Critical patent/JP2013508388A5/ja
Application granted granted Critical
Publication of JP5951490B2 publication Critical patent/JP5951490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012535338A 2009-10-21 2010-10-20 非複合ボツリヌス神経毒素を精製するための方法およびシステム Active JP5951490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25381009P 2009-10-21 2009-10-21
US61/253,810 2009-10-21
PCT/US2010/053389 WO2011050072A1 (en) 2009-10-21 2010-10-20 Methods and systems for purifying non-complexed botulinum neurotoxin

Publications (3)

Publication Number Publication Date
JP2013508388A JP2013508388A (ja) 2013-03-07
JP2013508388A5 JP2013508388A5 (enExample) 2013-09-26
JP5951490B2 true JP5951490B2 (ja) 2016-07-13

Family

ID=43879799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535338A Active JP5951490B2 (ja) 2009-10-21 2010-10-20 非複合ボツリヌス神経毒素を精製するための方法およびシステム

Country Status (24)

Country Link
US (5) US20120196349A1 (enExample)
EP (1) EP2490986B2 (enExample)
JP (1) JP5951490B2 (enExample)
KR (1) KR101819129B1 (enExample)
CN (2) CN104961812B (enExample)
AU (1) AU2010310749B2 (enExample)
BR (1) BR112012009227A2 (enExample)
CA (1) CA2773396C (enExample)
CO (1) CO6551670A2 (enExample)
CY (1) CY1120908T1 (enExample)
DK (1) DK2490986T4 (enExample)
ES (1) ES2688065T5 (enExample)
HR (1) HRP20181869T1 (enExample)
HU (1) HUE041599T2 (enExample)
IL (2) IL218532A (enExample)
LT (1) LT2490986T (enExample)
MX (3) MX2012004703A (enExample)
PH (1) PH12012500549A1 (enExample)
PL (1) PL2490986T3 (enExample)
PT (1) PT2490986T (enExample)
RS (1) RS58006B1 (enExample)
SI (1) SI2490986T1 (enExample)
SM (1) SMT201800487T1 (enExample)
WO (1) WO2011050072A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240317798A1 (en) * 2021-07-05 2024-09-26 Pharma Research Bio Co., Ltd. Method for purifying clostridium botulinum toxin complex protein

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
CN102869373B (zh) * 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
KR102272580B1 (ko) 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CA3124535A1 (en) 2018-12-21 2020-06-25 The Research Foundation For Microbial Diseases Of Osaka University Botulinum toxin producing method
KR102485146B1 (ko) 2019-04-15 2023-01-06 (주)제테마 보툴리눔 독소의 제조방법
KR102447441B1 (ko) * 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR20230146049A (ko) * 2021-02-26 2023-10-18 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 폴리펩티드를 제조하기 위한 세포 용해 버퍼 분리 장비, 시스템 및 이의 용도
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102512757B1 (ko) * 2021-07-22 2023-03-22 (주)이니바이오 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법
US20250018016A1 (en) * 2021-11-15 2025-01-16 Medytox Inc. Botulinum neurotoxin composition
TWI890364B (zh) * 2023-03-16 2025-07-11 南韓商大熊股份有限公司 使用多模式層析法純化肉毒毒素的改進方法
CN122514358A (zh) 2023-09-19 2026-08-04 雷文斯治疗公司 需要快速起效美容效果和更平滑皮肤外观的患者中的使用肉毒毒素的治疗
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
KR102945108B1 (ko) * 2024-06-19 2026-04-02 (주)제테마 클로스트리디움 보툴리눔 독소의 정제방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US796419A (en) 1904-07-18 1905-08-08 Carl Halbig Doll-head.
SE303567B (enExample) * 1959-02-17 1968-09-02 Behringwerke Ag
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
WO1999037326A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) † 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
DK1301213T3 (en) * 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
GB2386246B (en) 2001-11-01 2005-06-29 Marconi Applied Techn Ltd Electron beam tube apparatus
US7118901B2 (en) * 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
KR100498964B1 (ko) 2003-03-05 2005-07-01 삼성전자주식회사 이동단말에서의 전자파 흡수율 제어 방법 및 장치
AU2003271835A1 (en) * 2003-06-06 2005-01-04 Avecia Limited Process for the separation of proteins
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
JP2007535911A (ja) * 2003-12-30 2007-12-13 バハラ バイオテック インターナショナル リミテッド 組換えタンパク質の製造及び精製方法
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
HUE025656T2 (en) * 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) * 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
CN1930186A (zh) * 2005-03-03 2007-03-14 阿勒根公司 为获得梭菌毒素的梭菌细菌培养基及方法
HRP20090382T1 (hr) * 2005-06-17 2009-09-30 Merz Pharma Gmbh & Co.Kgaa Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP2085093B1 (en) * 2006-10-27 2015-02-25 The Chemo-Sero-Therapeutic Research Institute Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen
CN100588706C (zh) * 2007-04-06 2010-02-10 常州千红生化制药股份有限公司 纯化弹性蛋白酶的方法
AU2008256418A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
LT2379104T (lt) * 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
CN102869373B (zh) * 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
US8440104B2 (en) * 2009-10-21 2013-05-14 General Electric Company Kimzeyite garnet phosphors
US20150204884A1 (en) * 2012-06-01 2015-07-23 Momenta Pharmaceuticals, Inc. Methods of evaluating and making biologics
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
CN109069608A (zh) * 2015-10-29 2018-12-21 雷文斯治疗公司 具有长的治疗或美容效应持续时间的可注射肉毒杆菌毒素制剂以及其使用方法
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
AU2018270092C1 (en) * 2017-05-18 2026-01-08 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240317798A1 (en) * 2021-07-05 2024-09-26 Pharma Research Bio Co., Ltd. Method for purifying clostridium botulinum toxin complex protein

Also Published As

Publication number Publication date
US20170029795A1 (en) 2017-02-02
US20110092682A1 (en) 2011-04-21
CO6551670A2 (es) 2012-10-31
DK2490986T3 (en) 2018-11-05
CA2773396C (en) 2020-12-15
PT2490986T (pt) 2018-11-13
PL2490986T3 (pl) 2019-03-29
IL218532A (en) 2016-10-31
EP2490986B2 (en) 2024-04-24
US20200277591A1 (en) 2020-09-03
CY1120908T1 (el) 2019-12-11
EP2490986A1 (en) 2012-08-29
HUE041599T2 (hu) 2019-05-28
IL248486A0 (en) 2016-12-29
US20150322419A1 (en) 2015-11-12
US20120196349A1 (en) 2012-08-02
PH12012500549A1 (en) 2017-08-23
LT2490986T (lt) 2018-11-26
RS58006B1 (sr) 2019-02-28
MX2019006519A (es) 2019-09-18
KR101819129B1 (ko) 2018-02-28
US11466262B2 (en) 2022-10-11
HK1215951A1 (zh) 2016-09-30
ES2688065T3 (es) 2018-10-30
KR20120099431A (ko) 2012-09-10
HRP20181869T1 (hr) 2019-01-11
EP2490986A4 (en) 2013-11-13
JP2013508388A (ja) 2013-03-07
CN104961812A (zh) 2015-10-07
SI2490986T1 (sl) 2018-12-31
ES2688065T5 (es) 2024-10-04
SMT201800487T1 (it) 2019-01-11
AU2010310749A1 (en) 2012-03-29
CN102666396A (zh) 2012-09-12
BR112012009227A2 (pt) 2016-08-23
EP2490986B1 (en) 2018-08-08
HK1175453A1 (en) 2013-07-05
CN104961812B (zh) 2019-08-20
CN102666396B (zh) 2015-05-13
MX365496B (es) 2019-06-05
CA2773396A1 (en) 2011-04-28
IL218532A0 (en) 2012-07-31
MX2012004703A (es) 2012-06-08
WO2011050072A1 (en) 2011-04-28
US9469849B2 (en) 2016-10-18
AU2010310749B2 (en) 2016-02-11
DK2490986T4 (da) 2024-06-17

Similar Documents

Publication Publication Date Title
US11466262B2 (en) Methods and systems for purifying non-complexed botulinum neurotoxin
JP5518024B2 (ja) 動物由来産物不含方法およびボツリヌス毒素を精製するための方法
JP6704329B2 (ja) ボツリヌス神経毒素を得るためのプロセスおよびシステム
KR20200121247A (ko) 보툴리눔 독소의 제조방법
HK1215951B (en) Methods and systems for purifying non-complexed botulinum neurotoxin
HK1175453B (en) Methods and systems for purifying non-complexed botulinum neurotoxin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160608

R150 Certificate of patent or registration of utility model

Ref document number: 5951490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250